Why Is RXO INC (RXO) Stock Down Today?

RXO stock fell 5.93% to $24.11 in intraday trading as TD Cowen downgraded the stock to Sell citing liability risks. The downgrade came within a broader context of mixed analyst coverage and ongoing unprofitability for the company. With a market capitalization of $4.2 billion and a trailing twelve-month EPS of -0.62, RXO continues to operate at a loss despite a 13.1% year-to-date revenue increase.

What Happened

TD Cowen’s downgrade to Sell marked a significant shift in sentiment for RXO, highlighting concerns over potential liabilities. This move followed a recent coverage update from Goldman Sachs, which maintained a Neutral stance but raised its price target to $20. Meanwhile, Truist Securities and Susquehanna also adjusted their price targets, with Truist raising its Buy rating to $30 and Susquehanna keeping a Negative rating while raising its target to $20. BMO Capital added to the coverage mix by initiating coverage with an Outperform rating and a $35 price target. These varied analyst actions reflect a divided view of RXO’s near-term prospects.

RXO’s stock has faced additional pressure from its weak fundamentals, including a net margin of -1.8% and a beta of 1.92, which indicates high volatility relative to the market. The stock has traded between $10.43 and $29.90 over the past 52 weeks, and the recent decline has brought it closer to its lower end of that range.

What To Watch

RXO will need to demonstrate stronger earnings and improved operational performance to reverse the current downtrend. Investors should monitor upcoming analyst commentary and any developments in the company’s liability management. Coverage breadth remains active, with multiple firms adjusting their positions and price targets in recent days.